Revolution Medicines (RVMD) Cash from Operations (2019 - 2026)

Revolution Medicines has reported Cash from Operations for 8 years, with the latest figure at -$387.3 million in Q2 2026.

• On a quarterly basis, Cash from Operations fell 74.66% year-over-year to -$387.3 million in Q2 2026; TTM through Jun 2026 was -$1.2 billion, a 78.57% decrease from a year earlier, with the FY2025 full-year figure at -$897.7 million, down 61.05% from the prior year.
• Cash from Operations was -$387.3 million for Q2 2026 at Revolution Medicines, down from -$354.2 million in the prior quarter.
• The five-year high for Cash from Operations was -$51.7 million in Q3 2022, with the low at -$387.3 million in Q2 2026.
• Average Cash from Operations over 5 years is -$154.0 million, with a median of -$129.3 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations retreated 13.11% in 2023, then sank 157.34% in 2024.
• Over 5 years, Cash from Operations stood at -$61.8 million in 2022, then slumped by 95.12% to -$120.6 million in 2023, then fell by 14.7% to -$138.3 million in 2024, then tumbled by 98.31% to -$274.2 million in 2025, then plunged by 41.23% to -$387.3 million in 2026.
• The last three Cash from Operations figures came in at -$387.3 million (Q2 2026), -$354.2 million (Q1 2026), and -$274.2 million (Q4 2025), per Business Quant data.